Finance

Lists
AMGN34:BVMF
Amgen Inc. BDR
72,00 BRL
0,00%
(0,00) 1D
5-окт., 16:38:37 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Mkt. cap
218,80 млд
Avg. vol.
405,00
Volume
0,00
52-wk high
83,06 BRL
52-wk low
47,76 BRL
Shares outstanding
540,63 млн
No. of employees
32 миң
Mkt. cap
218,80 млд
Avg. vol.
405,00
Volume
0,00
52-wk high
83,06 BRL
52-wk low
47,76 BRL
Shares outstanding
540,63 млн
No. of employees
32 миң
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31,5 миң
Founded1980
HeadquartersТаусанд Окс, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteamgen.com
Last report
2026-ж., 4-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
6,29 USD / 5,62 USD
+11,97%beat
Revenue / Est. (USD)
10,05 млд / 9,42 млд
+6,73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
9,56 млд
9,87 млд
8,62 млд
10,05 млд
Cost of goods sold
2,74 млд
2,68 млд
2,50 млд
2,75 млд
Cost of revenue
2,74 млд
2,68 млд
2,50 млд
2,75 млд
Research and development expenses
1,90 млд
2,14 млд
1,72 млд
1,87 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,72 млд
1,95 млд
1,60 млд
1,74 млд
Operating expense
3,55 млд
4,18 млд
3,21 млд
3,73 млд
Total operating expenses
6,29 млд
6,85 млд
5,70 млд
6,48 млд
Operating income
3,26 млд
3,01 млд
2,91 млд
3,57 млд
Other non operating income
181,00 млн
143,00 млн
192,00 млн
145,00 млн
EBT including unusual items
3,92 млд
1,51 млд
2,08 млд
2,77 млд
EBT excluding unusual items
2,72 млд
2,51 млд
2,37 млд
3,06 млд
Income tax expense
705,00 млн
181,00 млн
265,00 млн
393,00 млн
Effective tax rate
17,98%
11,96%
12,72%
14,20%
Other operating expenses
-71,00 млн
82,00 млн
-113,00 млн
116,00 млн
Net income
3,22 млд
1,33 млд
1,82 млд
2,38 млд
Net profit margin
33,65%
13,51%
21,11%
23,62%
Earnings per share
5,64
5,29
5,15
6,29
Interest and investment income
-
408,00 млн
-
-
Interest expense
-685,00 млн
-1,06 млд
-657,00 млн
-673,00 млн
Net interest expenses
-685,00 млн
-653,00 млн
-657,00 млн
-673,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,57 млд
4,02 млд
4,03 млд
4,69 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору